Projects funded by the NCN


Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Determination of the mechanisms and potential targets for neuropathic pain therapy by investigating pharmacological interactions occurring between substances that modulates glial cells activity and opioid analgesics.

2016/23/N/NZ7/00356

Keywords:

neuropathic pain CCR5 CXCR3 chemokines interleukins opioids

Descriptors:

  • NZ7_14: Pharmacy, pharmacotherapy, pharmacology
  • NZ7_16: Other related subjects

Panel:

NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology

Host institution :

Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk

woj. małopolskie

Other projects carried out by the institution 

Principal investigator (from the host institution):

Anna Piotrowska-Murzyn 

Number of co-investigators in the project: 3

Call: PRELUDIUM 12 - announced on 2016-09-15

Amount awarded: 149 400 PLN

Project start date (Y-m-d): 2017-08-17

Project end date (Y-m-d): 2022-08-16

Project duration:: 60 months (the same as in the proposal)

Project status: Project settled

Project description

Download the project description in a pdf file

Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Information in the final report

  • Publication in academic press/journals (5)
  • Articles in post-conference publications (10)
  1. New insights into the analgesic properties of the XCL1/XCR1 and XCL1/ITGA9 axes modulation under neuropathic pain conditions - evidence from animal studies.
    Authors:
    Ciechanowska A., Rojewska E., Piotrowska A., Barut J., Pawlik K., Ciapała K., Kreiner G., Mika J.
    Academic press:
    Frontiers in Immunology (rok: 2022, tom: 13, strony: 1058204), Wydawca: Frontiers
    Status:
    Published
    DOI:
    10.3389/fimmu.2022.1058204 - link to the publication
  2. Pharmacological blockade of CXCR3 by (±)-NBI-74330 reduces neuropathic pain and enhances opioid effectiveness - Evidence from in vivo and in vitro studies.
    Authors:
    Piotrowska A., Rojewska E., Pawlik K., Kreiner G., Ciechanowska A., Makuch W., Zychowska M, Mika J.
    Academic press:
    Biochimica et Biophysica Acta - Molecular Basis of Disease (rok: 2018, tom: 1864, strony: 3418-3437), Wydawca: Elsevier
    Status:
    Published
    DOI:
    10.1016/j.bbadis.2018.07.032. - link to the publication
  3. Dataset of (±)-NBI-74330 (CXCR3 antagonist) influence on chemokines under neuropathic pain
    Authors:
    Piotrowska A., Rojewska E., Pawlik K., Kreiner G., Ciechanowska A., Makuch W., Mika J.
    Academic press:
    Data in Brief (rok: 2018, tom: 21, strony: 1145–1150), Wydawca: Elsevier
    Status:
    Published
  4. Comparison of the Effects of Chemokine Receptors CXCR2 and CXCR3 Pharmacological Modulation in Neuropathic Pain Model-In Vivo and In Vitro Study.
    Authors:
    Piotrowska A., Ciapała K., Pawlik K., Kwiatkowski K., Rojewska E., Mika J.
    Academic press:
    International Journal of Molecular Sciences (rok: 2021, tom: 22, strony: 11074), Wydawca: MDPI
    Status:
    Published
    DOI:
    10.3390/ijms222011074 - link to the publication
  5. Pharmacological Blockade of Spinal CXCL3/CXCR2 Signaling by NVP CXCR2 20, a Selective CXCR2 Antagonist, Reduces Neuropathic Pain Following Peripheral Nerve Injury
    Authors:
    Piotrowska A., Rojewska E., Pawlik K., Kreiner G., Ciechanowska A., Makuch W., Nalepa I, Mika J.
    Academic press:
    Frontiers in Immunology (rok: 2019, tom: 10, strony: 45313), Wydawca: Frontiers
    Status:
    Published
    DOI:
    10.3389/fimmu.2019.02198 - link to the publication
  1. Pharmacological blockade of CXCR3 by (±)-NBI-74330 reduces neuropathic pain.
    Authors:
    Pawlik K., Piotrowska A., Rojewska E., Ciechanowska A., Makuch W., Mika J.
    Conference:
    3rd Central European Biomedical Congress (rok: 2018, ), Wydawca: CEBC, Kraków 2018
    Data:
    konferencja 15-18.09.2018
    Status:
    Published
  2. Blockade of CXCR3 by (±)-NBI-74330 inhibits neuropathic pain in rats by modulating release of CXCR3 ligands.
    Authors:
    Piotrowska A, Rojewska E, Zychowska M., Makuch W., Mika J.
    Conference:
    Neuronus 2018 (rok: 2018, ), Wydawca: Neuronus IBRO NEUROSCIENCE FORUM
    Data:
    konferencja 20-22.04.2018
    Status:
    Published
  3. The (±)-NBI-74330 (CXCR3 antagonist) reduces neuropathic pain and influences the level of nociceptive factors – evidence from in vivo and in vitro studies
    Authors:
    Pawlik K., Piotrowska A., Rojewska E., Popiołek- Barczyk K., Mika J.
    Conference:
    Neuronus 2018 (rok: 2018, ), Wydawca: Neuronus IBRO NEUROSCIENCE FORUM
    Data:
    konferencja 20-22.04.2018
    Status:
    Published
  4. The effects of opioids on immune system – the role of glial cells in the development of opioid tolerance and OIH in the model of neuropathic pain.
    Authors:
    Piotrowska A., Bogacka J., Starnowska-Sokół J., Ciapała K., Przewłocka B.
    Conference:
    12th Congress of the European Pain Federation EFIC (rok: 2022, ), Wydawca: EFIC
    Data:
    konferencja 27.04-01.05.2022
    Status:
    Published
  5. Porównanie wpływu farmakologicznej modulacji receptorów chemokinowych z rodziny CXC na proces nocycepcji w bólu neuropatycznym.
    Authors:
    Piotrowska-Murzyn A., Rojewska E., Pawlik K., Ciechanowska A., Mika J.
    Conference:
    VIII Sympozjum "Postępy w leczeniu bólu" Polskiego Towarzystwa Badania Bólu (rok: 2021, ), Wydawca: medycyna praktyczna mp.pl
    Data:
    konferencja 18-27.11.2021
    Status:
    Published
  6. Antagoniści receptorów chemokinowych jako modulatory komórek glejowych w bólu neuropatycznym.
    Authors:
    Piotrowska A., Rojewska E., Pawlik K., Kwiatkowski K., Ciechanowska A., Makuch W., Mika J.
    Conference:
    VII SYMPOZJUM "POSTĘPY W LECZENIU BÓLU" (rok: 2018, ), Wydawca: INDEX COPERNICUS
    Data:
    konferencja 4-6.10.2018
    Status:
    Published
  7. Blockade of CXCR2 inhibits neuropathic pain – related behavior and modulates primary microglial and astroglia culture
    Authors:
    Pawlik K., Piotrowska A., Rojewska E., Ciechanowska A., Makuch W., Mika J.
    Conference:
    European Meeting on Glial Cells in Health and Disease (rok: 2019, ), Wydawca: Wiley Online Library
    Data:
    konferencja 2019-07-10-13
    Status:
    Published
  8. Comparison of antinociceptive effects of CXCR2 and CXCR3 receptor antagonists and their influence on opioids analgesia of neuropathic pain model.
    Authors:
    Piotrowska A., Rojewska E., Pawlik K., Ciechanowska A., Makuch W., Mika J.
    Conference:
    Pain in Europe XI, 11th Congress of the European Pain Federation EFIC, Walencja, Hiszpania (rok: 2019, ), Wydawca: EFIC
    Data:
    konferencja 2019-09-4-7
    Status:
    Published
  9. CXCR3 receptor as new target to treat neuropathic pain: efficacy of a receptor antagonist in in vitro and in vivo studies
    Authors:
    Piotrowska A., Kwiatkowski K., Rojewska E., Pawlik K., Ciechanowska A., Mika J.
    Conference:
    European Pain Federation Krakow Pain School, EFIC School 2019, Translational Pain Research "From Lab to clinic" (rok: 2019, ), Wydawca: Index Copernicus International
    Data:
    konferencja 2019-06-22-27
    Status:
    Published
  10. Comparison of pharmacological modulation of glial cells by the CCR5 and CXCR3 receptor antagonists –in vivo and in vitro studies
    Authors:
    Piotrowska-Murzyn A., Kwiatkowski K., Rojewska E., Pawlik K., Ciechanowska A., Mika J.
    Conference:
    European Meeting on Glial Cells in Health and Disease (rok: 2019, ), Wydawca: Wiley Online Library
    Data:
    konferencja 2019-07-10-13
    Status:
    Published